IDH1 and glioblastoma: Haematological markers compared to molecular prognostic markers, such as IDH1 mutation [18], mRNA-profiles [19] and NMR spectroscopy-based metabolomics of blood cells [20] can be used to assess the prognosis of GBM patients in order to guide decisions on further therapeutic procedures.